dr. mary-ellen taplin on the mechanism of action of enzalutamide (mdv3100)
Published 11 years ago • 2.2K plays • Length 1:34Download video MP4
Download video MP3
Similar videos
-
1:39
dr. mary-ellen taplin on abiraterone acetate's mechanism of action
-
1:21
dr. shore on the enzalutamide mechanism of action
-
3:10
dr. mary-ellen taplin on dual pathway inhibition in prostate cancer
-
1:49
dr. mary-ellen taplin on neoadjuvant adt plus hormonal therapy for prostate cancer
-
1:41
dr. mary-ellen taplin on neoadjuvant abiraterone acetate and leuprolide acetate
-
2:11
dr. mary-ellen taplin on treating prostate/gu cancers | dana-farber cancer institute
-
5:29
key considerations for the vision trial of lupsma in mcrpc | mary-ellen taplin
-
1:40
helping patients make the best choice for them: dr. mary-ellen taplin | dana-farber cancer institute
-
21:55
dr christian frezza - mitochondrial dysfunction in cancer
-
29:08
neuro lecture: tpa and thrombectomy with dr. alex merkler
-
19:11
theranostics: the future for prostate cancer treatment is here!!
-
25:25
biologic rationale for next-generation ar inhibitors - mary-ellen taplin
-
1:02
dr. robert dreicer discusses sequencing mdv3100 and abiraterone
-
5:42
treatments for post-docetaxel prostate cancer, part ii
-
1:22
dr. james mohler discusses prostate cancer trial endpoints
-
1:12
dr. dreicer on the current role of abiraterone and enzalutamide in prostate cancer
-
1:26
dr. sonpavde on remaining questions with immunotherapy in bladder cancer
-
4:36
nonmetastatic crpc: considerations for apalutamide
-
1:03
dr. daniel petrylak on the role of enzalutamide in prostate cancer
-
1:28
dr. alter discusses provenge moa and tolerability
-
13:04
androgen receptor-targeted ttherapies in advanced prostate cancer
-
3:19
what are the effects of the treatment on cml ?